Services SUPPORT Online inquiry

For Research Use Only. Not For Clinical Use.

Contact us
  • Email:

iPSC Genome Editing Services

Overview Service Features FAQs Scientific Resources Related Services

Overview

Nowadays, the application of custom-engineered sequence-specific nucleases enables genetic changes in human cells to be easily made with much greater efficiency and precision, such as CRISPR/Cas9, and TALEN. Engineered double-stranded DNA breaks are able to efficiently disrupt genes, also which can be realized by the right donor vector, engineer point mutations, as well as gene insertions. Nevertheless, in order to ensure the maximum gene targeting efficiency and specificity, a great variety of design considerations should be taken into account. It is especially important when engineering induced pluripotent stem cells (iPSCs), because they are more difficult to transfect and less resilient to DNA damage than immortalized tumor cell lines. With years of exploration in iPSC development, Creative Biolabs is dedicated to providing a full range of iPSC genome editing services for customers all over the world.

Viral Vectors

Viral vectors are good candidate to be used for transient transfection. Generally, lentiviral vectors are utilized to bring Cas9 and sgRNA components into a great number of cell types, both dividing and non-dividing. Besides, integrase-deficient lentiviral vectors (IDLV) have also been applied to deliver nucleases and homologous donor templates to edit iPSCs, these vectors can deliver gene constructs which do no integrate into the genome and are gradually lost during cell division. Moreover, adenoviral vectors are able to be used to edit human stem cells in vitro, because they can transduce a number of dividing and non-dividing cells.

Transcription Activator-like Effector Nucleases (TALENs)

Xanthomonas is a genus of Proteobacteria, it utilizes the type III secretion system to inject effector proteins into plant cells, in order to overcome and reprogram the cellular machinery of the host. A set of these effector proteins, named transcription activator-like effectors (TALEs), are targeted to the nucleus. TALEs are hybrid proteins comprised of DNA-binding modules from TALE proteins and the FokI catalytic domain for the production of site-specific DSBs. In order to introduce a site-specific DSB into the genome, two TALENs should be engineered to bind to the forward and reverse strands with an optimal spacer sequence to enable dimerization of the FokI domain, leading to the formation of DSBs.

Part a shows the ZFNs based genome editing approach, Part b shows the TALENs based genome editing approach, Part c shows the Crisprs/Cas systems based genome editing method. (Eid, A., 2016)Fig. 1 Part a shows the ZFNs based genome editing approach, Part b shows the TALENs based genome editing approach, Part c shows the Crisprs/Cas systems based genome editing method. (Eid, A., 2016)

Crispr/crispr-associated-9

Bacteria and archaea fend off invading nucleic acids from phages and conjugative plasmids by using clustered regularly interspaced palindromic repeats Crisprs/Cas systems. The CRISPR adaptive immunity systems function via the orchestrated and cooperative activities of several proteins to target invading nucleic acids, such as DNA or RNA.

CRISPR/Cas systems act as molecular immunity machinery to keep a molecular record of previous invaders through a short spacer sequence. The function of this spacer sequence is targeting and destroying invading nucleic acids (CRISPR RNA or crRNA) in future invasions. There are a variety number of CRISPR/Cas systems which primarily target DNA and or RNA molecules in various ways via multi-ribonucleoprotein complexes. Therefore, this system has been widely used to edit the genomes of a diverse array of mammalian cell types and organisms with great efficiency and precision, including iPSCs.

With our advanced iPSC development platform, we offer high quality custom-built iPSC genome editing services, to help customers reach the following goals.

  • Knock-out a gene of interest
  • Knock-in a disease-associated point mutation
  • Tag a gene of interest with reporters you required
  • Reversion to wildtype in disease-derived iPS line

With professional scientists devoted themselves in iPSC genome editing, Creative Biolabs is dedicated to providing the first class genome editing services of iPSC for our customers. Please contact us for more information and a detailed quote.

Features of Our Services

As a stem cell biotechnology company, we take immense pride in our iPSC genome editing services. Here are some of the key features:

  • Customized genetic modifications - Our services allow for the precise, custom modification of the genome within induced pluripotent stem cells. This includes genetic knock-outs, knock-ins, point mutations or gene corrections, and sequences insertion, etc.
  • Advanced technology – Our team utilizes cutting-edge CRISPR/Cas9 and TALEN technologies for genome editing. These technologies provide us with the capability to precisely target and edit genes in iPSCs.
  • Comprehensive workflow - Our service includes all stages of the iPSC genome editing process - from guide RNA design and construction, clone generation, and verification of the genomic alteration, right through to the validation of modified clones.
  • High efficiency & precision - We use the most advanced protocols and techniques that ensure high editing efficiency and precision, to produce clones with the desired genetic alterations with minimal off-target effects.
  • High standard quality control - Every batch of iPSCs goes through stringent quality control tests to ensure the highest standards of pluripotency, sterility and mycoplasma. We even analyze the genomic stability of each line using karyotype testing.

Every project concludes with rigorous quality control, followed by validation to ensure that the precise genetic alteration was made without off-target effects. We offer full project support from our team of experienced stem cell biologists, ensuring smooth communication and execution of your project requirements.

Apart from the regular service, we offer post-delivery support to help troubleshoot any issues that clients may encounter while working with the engineered iPSCs. These are part of our commitment to providing the best quality services to our clients who are at the forefront of stem cell research and therapeutic development.

FAQs

  • Q: Can you provide custom iPSC genome editing as per my research requirements?
    A: Yes, we can. Our team will coordinate with you to understand your exact requirements and will tailor our iPSC Genome Editing Service to fit your research.
  • Q: Do you provide any guarantees for your genome editing service?
    A: We strive to provide high-quality services, and while we can't guarantee results due to the inherent uncertainties involved in scientific research, we promise professionalism, precise genome editing, and comprehensive support throughout the project.
  • Q: Can you edit any specific gene of my choice in iPSCs? And how long does it usually take to complete the iPSC genome editing process?
    A: Yes, we can. Whether it's knocking in, knocking out, or modifying specific genes, our state-of-the-art CRISPR-Cas9 technology allows us to carry out precise genetic modifications based on your research requirements. The duration of the process largely depends on the complexity of the required genetic modifications. Generally, it ranges from a few weeks to several months.
  • Q: Do you provide any post-editing services, like validation or phenotypic analysis?
    A: Yes, we do. Additional services including validation of the genetic modification and phenotypic analysis are available. These services can provide more reliable and interpretable research outcomes.
  • Q: How is the efficiency of the iPSC genome editing procedure evaluated?
    A: We use techniques like T7E1 assay, Sanger sequencing, or Next-generation sequencing (NGS) to detect and measure gene modification. These tests help us ensure that the editing is efficient and precise.

Scientific Resources

Reference

  1. Eid, A., (2016). “Genome editing: the road of CRISPR/Cas9 from bench to clinic.” Experimental & molecular medicine, 48(10), e265.

For Research Use Only. Not For Clinical Use.